Trovagene Inc. (NASDAQ:TROV) shares saw unusually-high trading volume on Wednesday . Approximately 386,357 shares traded hands during mid-day trading, an increase of 27% from the previous session’s volume of 304,625 shares.The stock last traded at $5.01 and had previously closed at $4.84.

TROV has been the topic of several research reports. Avondale Partners reissued a “market perform” rating and issued a $6.00 target price on shares of Trovagene in a report on Tuesday, March 29th. Maxim Group reissued a “buy” rating on shares of Trovagene in a report on Monday, June 6th. Piper Jaffray Cos. lowered Trovagene from an “overweight” rating to a “neutral” rating and upped their target price for the company from $5.26 to $8.00 in a report on Monday, April 25th. Leerink Swann reissued a “hold” rating on shares of Trovagene in a report on Thursday, May 12th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 target price on shares of Trovagene in a report on Monday, March 28th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $6.96.

The company’s 50 day moving average price is $4.76 and its 200-day moving average price is $4.76. The company’s market cap is $148.71 million.

Trovagene (NASDAQ:TROV) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. On average, equities research analysts expect that Trovagene Inc. will post ($1.30) EPS for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.